A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

NCT04610125 ·Status: UNKNOWN ·Phase: NA

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

NCT04814004 ·Status: UNKNOWN ·Phase: PHASE1

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04648475 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04649983 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160 ·Status: UNKNOWN ·Phase: NA

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

NCT04287309 ·Status: UNKNOWN

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia

NCT07233018 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT04026100 ·Status: UNKNOWN ·Phase: PHASE1

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

NCT04532281 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

NCT03544021 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

NCT04272125 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

NCT05745181 ·Status: RECRUITING ·Phase: PHASE2

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03121625 ·Status: UNKNOWN ·Phase: PHASE1

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT04532203 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

NCT04196205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

NCT04007978 ·Status: UNKNOWN ·Phase: PHASE1

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07234045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT05651100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03312205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

NCT04714593 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2